TXMD THERAPEUTICSMD INC revenue, earnings and financials

For the quarter ended June 30, 2026, THERAPEUTICSMD INC reported revenue of $869K (down 8.7% from a year earlier), net income of $155K and diluted EPS of $0.01; over the last four quarters revenue was $3.27M and net income −$217K; for the fiscal year ended December 2025 revenue was $3.02M, up 71.6% on the year before.

TXMD annual revenue and earnings

• Fiscal year ended Dec 2025: revenue $3.02M, gross profit n/a, operating income −$4.39M, net income −$569K (margin -18.8%), EPS −$0.05
• Fiscal year ended Dec 2024: revenue $1.76M, gross profit n/a, operating income −$6.11M, net income −$2.18M (margin -123.9%), EPS −$0.19
• Fiscal year ended Dec 2023: revenue $1.30M, gross profit $1.30M, operating income −$8.52M, net income −$10.3M (margin -789.4%), EPS −$0.99
• Fiscal year ended Dec 2022: revenue $70.0M, gross profit $68.6M, operating income $1.19M, net income $112M (margin 160.1%), EPS $11.96
• Fiscal year ended Dec 2021: revenue $2.57M, gross profit $1.17M, operating income −$79.6M, net income −$172M (margin -6700.9%), EPS −$21.66

TXMD quarterly revenue and earnings

• Quarter ended Jun 30, 2026: revenue $869K (down 8.7% year over year), net income $155K, EPS $0.01
• Quarter ended Mar 31, 2026: revenue $724K (up 84.2% year over year), net income $95.0K, EPS $0.01
• Quarter ended Dec 31, 2025 (from the annual report): revenue $893K (up 33.9% year over year), net income −$619K, EPS −$0.05
• Quarter ended Sep 30, 2025: revenue $784K (up 43.3% year over year), net income $152K, EPS $0.01
• Quarter ended Jun 30, 2025: revenue $952K (up 306.8% year over year), net income $551K, EPS $0.05
• Quarter ended Mar 31, 2025: revenue $393K (up 25.6% year over year), net income −$653K, EPS −$0.06
• Quarter ended Dec 31, 2024 (from the annual report): revenue $667K (up 32.9% year over year), net income $252K, EPS $0.01
• Quarter ended Sep 30, 2024: revenue $547K (up 1132.1% year over year), net income −$609K, EPS −$0.05
• Quarter ended Jun 30, 2024: revenue $234K (down 46.5% year over year), net income −$1.09M, EPS −$0.09
• Quarter ended Mar 31, 2024: revenue $313K (down 24.8% year over year), net income −$734K, EPS −$0.06
• Quarter ended Dec 31, 2023 (from the annual report): revenue $502K (down 99.3% year over year), net income −$883K, EPS −$0.06
• Quarter ended Sep 30, 2023: revenue −$53.0K (down 115.0% year over year), net income −$3.38M, EPS −$0.32
• Quarter ended Jun 30, 2023: revenue $437K (up 25.6% year over year), net income −$2.41M, EPS −$0.24
• Quarter ended Mar 31, 2023: revenue $416K (down 40.1% year over year), net income −$3.60M, EPS −$0.37
• Quarter ended Dec 31, 2022 (from the annual report): revenue $68.6M (up 267.1% year over year), net income $77.7M, EPS $7.96
• Quarter ended Sep 30, 2022: revenue $354K (down 98.6% year over year), net income −$29.0M, EPS −$3.13
• Quarter ended Jun 30, 2022: revenue $348K (down 98.5% year over year), net income $112M, EPS $12.83
• Quarter ended Mar 31, 2022: revenue $695K (down 96.5% year over year), net income −$49.0M, EPS −$5.70
• Quarter ended Dec 31, 2021: revenue $18.7M, net income −$43.0M, EPS −$0.10
• Quarter ended Sep 30, 2021: revenue $25.4M, net income −$47.4M, EPS −$5.62

TXMD cash flow, buybacks and dividends

• Fiscal year ended Dec 2021: operating cash flow −$143M, share buybacks n/a

TXMD balance sheet

• Jun 30, 2026: cash n/a, total assets $37.5M, total liabilities $10.4M, shareholders' equity $27.1M
• Mar 31, 2026: cash n/a, total assets $37.6M, total liabilities $10.6M, shareholders' equity $27.0M
• Dec 31, 2025: cash n/a, total assets $37.7M, total liabilities $10.8M, shareholders' equity $26.9M
• Sep 30, 2025: cash n/a, total assets $38.7M, total liabilities $11.2M, shareholders' equity $27.4M
• Jun 30, 2025: cash n/a, total assets $38.5M, total liabilities $11.2M, shareholders' equity $27.3M
• Mar 31, 2025: cash $5.75M, total assets $38.2M, total liabilities $11.5M, shareholders' equity $26.7M
• Dec 31, 2024: cash $5.06M, total assets $38.8M, total liabilities $11.5M, shareholders' equity $27.4M
• Jun 30, 2024: cash n/a, total assets $40.1M, total liabilities $12.5M, shareholders' equity $27.7M

What is TXMD's revenue?

THERAPEUTICSMD INC reported $3.27M of revenue over its last four quarters, through June 30, 2026.

Is TXMD profitable?

No. THERAPEUTICSMD INC lost $217K over the last four quarters.

What is TXMD's EPS?

Diluted earnings per share over the last four quarters were −$0.02; $0.01 in the latest quarter.

TXMD ownership and insider trades · All stocks